Unicycive Therapeutics Inc
Biotechnology
Unicycive Therapeutics Inc (UNCY) Stock News
The latest UNCY headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who have suffered losses are encouraged to contact the firm.
- GlobeNewswire Inc.·
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors
Johnson Fistel is investigating Unicycive Therapeutics after the FDA issued a second Complete Response Letter on June 30, 2026, citing the same third-party manufacturing deficiencies from a prior CRL. The FDA had not yet inspected the manufacturing vendor at the time of the resubmission. The announcement led to a decline in Unicycive's stock price, prompting investigation into potential false or misleading statements.